BioSpace News Archive

Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, MD, PhD, to its Strategic Advisory Board, effective today.

Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy.

Solasia Pharma K.K. and Nippon Kayaku Co., Ltd. jointly announced the conclusion of a license agreement for marketing rights to darinaparsin in Japan.

EyeGate Pharmaceuticals, Inc. today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. (“Bayon”) and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021.

Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that the last participant has completed the 26-week dosing period and 30-day safety follow up visit in the GEM-3 study, Krystal’s pivotal Phase 3 clinical trial evaluating investigational beremagene geperpavec (B-VEC) as a topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB).

FibroGen, Inc. will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close.

Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the third quarter 2021 on Tuesday, Nov. 2 at 9 a.m., ET.

Axcella Therapeutics (Nasdaq: AXLA), today announced a new clinical program to investigate AXA1125 as a potential treatment for patients with Long COVID, a complex condition also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC).

Innate Pharma SA released its 2022 financial calendar. All financial reports are released before market open CET.

The global structural biology and molecular modeling techniques market has been thriving due to the high prevalence of chronic diseases.